PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies

Abstract Background Neovascular eye disease is characterized by pathological neovascularization, with clinical manifestations such as intraocular exudation, bleeding, and scar formation, ultimately leading to blindness in millions of individuals worldwide. Pathologic ocular angiogenesis often occurs...

Full description

Bibliographic Details
Main Authors: Peiyu Liu, Dandan Sun, Shuchang Zhang, Shimei Chen, Xiaoqian Wang, Huiming Li, Fang Wei
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cell & Bioscience
Subjects:
Online Access:https://doi.org/10.1186/s13578-024-01205-9
_version_ 1797273106677497856
author Peiyu Liu
Dandan Sun
Shuchang Zhang
Shimei Chen
Xiaoqian Wang
Huiming Li
Fang Wei
author_facet Peiyu Liu
Dandan Sun
Shuchang Zhang
Shimei Chen
Xiaoqian Wang
Huiming Li
Fang Wei
author_sort Peiyu Liu
collection DOAJ
description Abstract Background Neovascular eye disease is characterized by pathological neovascularization, with clinical manifestations such as intraocular exudation, bleeding, and scar formation, ultimately leading to blindness in millions of individuals worldwide. Pathologic ocular angiogenesis often occurs in common fundus diseases including proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Anti-vascular endothelial growth factor (VEGF) targets the core pathology of ocular angiogenesis. Main body In recent years, therapies targeting metabolism to prevent angiogenesis have also rapidly developed, offering assistance to patients with a poor prognosis while receiving anti-VEGF therapy and reducing the side effects associated with long-term VEGF usage. Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key enzyme in targeted metabolism, has been shown to have great potential, with antiangiogenic effects and multiple protective effects in the treatment of neovascular eye disease. In this review, we summarize the mechanisms of common types of neovascular eye diseases; discuss the protective effect and potential mechanism of targeting PFKFB3, including the related inhibitors of PFKFB3; and look forward to the future exploration directions and therapeutic prospects of PFKFB3 in neovascular eye disease. Conclusion Neovascular eye disease, the most common and severely debilitating retinal disease, is largely incurable, necessitating the exploration of new treatment methods. PFKFB3 has been shown to possess various potential protective mechanisms in treating neovascular eye disease. With the development of several drugs targeting PFKFB3 and their gradual entry into clinical research, targeting PFKFB3-mediated glycolysis has emerged as a promising therapeutic approach for the future of neovascular eye disease.
first_indexed 2024-03-07T14:38:51Z
format Article
id doaj.art-73f4401577674bf28b4c37085a48c8a8
institution Directory Open Access Journal
issn 2045-3701
language English
last_indexed 2024-03-07T14:38:51Z
publishDate 2024-02-01
publisher BMC
record_format Article
series Cell & Bioscience
spelling doaj.art-73f4401577674bf28b4c37085a48c8a82024-03-05T20:28:58ZengBMCCell & Bioscience2045-37012024-02-0114111610.1186/s13578-024-01205-9PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategiesPeiyu Liu0Dandan Sun1Shuchang Zhang2Shimei Chen3Xiaoqian Wang4Huiming Li5Fang Wei6Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineShanghai General Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAbstract Background Neovascular eye disease is characterized by pathological neovascularization, with clinical manifestations such as intraocular exudation, bleeding, and scar formation, ultimately leading to blindness in millions of individuals worldwide. Pathologic ocular angiogenesis often occurs in common fundus diseases including proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Anti-vascular endothelial growth factor (VEGF) targets the core pathology of ocular angiogenesis. Main body In recent years, therapies targeting metabolism to prevent angiogenesis have also rapidly developed, offering assistance to patients with a poor prognosis while receiving anti-VEGF therapy and reducing the side effects associated with long-term VEGF usage. Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key enzyme in targeted metabolism, has been shown to have great potential, with antiangiogenic effects and multiple protective effects in the treatment of neovascular eye disease. In this review, we summarize the mechanisms of common types of neovascular eye diseases; discuss the protective effect and potential mechanism of targeting PFKFB3, including the related inhibitors of PFKFB3; and look forward to the future exploration directions and therapeutic prospects of PFKFB3 in neovascular eye disease. Conclusion Neovascular eye disease, the most common and severely debilitating retinal disease, is largely incurable, necessitating the exploration of new treatment methods. PFKFB3 has been shown to possess various potential protective mechanisms in treating neovascular eye disease. With the development of several drugs targeting PFKFB3 and their gradual entry into clinical research, targeting PFKFB3-mediated glycolysis has emerged as a promising therapeutic approach for the future of neovascular eye disease.https://doi.org/10.1186/s13578-024-01205-9PFKFB3Ocular angiogenesisGlycolysisEndothelial cellsOxidative stress
spellingShingle Peiyu Liu
Dandan Sun
Shuchang Zhang
Shimei Chen
Xiaoqian Wang
Huiming Li
Fang Wei
PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
Cell & Bioscience
PFKFB3
Ocular angiogenesis
Glycolysis
Endothelial cells
Oxidative stress
title PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
title_full PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
title_fullStr PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
title_full_unstemmed PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
title_short PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
title_sort pfkfb3 in neovascular eye disease unraveling mechanisms and exploring therapeutic strategies
topic PFKFB3
Ocular angiogenesis
Glycolysis
Endothelial cells
Oxidative stress
url https://doi.org/10.1186/s13578-024-01205-9
work_keys_str_mv AT peiyuliu pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT dandansun pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT shuchangzhang pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT shimeichen pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT xiaoqianwang pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT huimingli pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies
AT fangwei pfkfb3inneovasculareyediseaseunravelingmechanismsandexploringtherapeuticstrategies